Phase III Open Label Study of Tislelizumab Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First-line Treatment in Stage IIIB/IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 09 Aug 2018 According to a BeiGene media release, the first patient has been dosed in this trial.
- 09 Aug 2018 Status changed from not yet recruiting to recruiting, according to a BeiGene media release.
- 25 Jul 2018 New trial record